DOSSIER · 13F-HR · Q2 2026

PFIZER INC

$170M in tracked AUM across 20 positions as of Q2 2026.

PI
CIK 0000078003 · last filed Jun 30, 2026
Total AUM
$170M
as of Q2 2026
Holdings
20
positions
Whale Score
71
71
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Pfizer Inc. SEC 13F Filing (Q3 2025)
Portfolio Overview

The filing for Pfizer Inc. reveals a specialized investment portfolio totaling approximately $381.04 million as of September 30, 2025. This represents a significant contraction in portfolio value, decreasing by 33.9% from the previous quarter's $576.19 million. The portfolio is highly concentrated, containing only 15 holdings, which indicates a strategy focused on high-conviction investments rathe...

The drastic reduction in total portfolio value—nearly $195 million—is driven almost entirely by asset allocation decisions (specifically the reduction of a major holding) and the exit from several positions, rather than purely market depreciation. This suggests an active liquidity management strategy or a shift in capital deployment priorities for the parent company.

Key Holdings

The portfolio is dominated by a few large positions, creating a top-heavy structure.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
ALLO
ALLOGENE THERAPEUTICS INC
$47M22.0M27.5%
02
CELC
CELCUITY INC
$30M296K17.3%
03
ARVN
ARVINAS INC
$28M3.5M16.2%
04
PYXS
PYXIS ONCOLOGY INC
$19M7.0M11.4%
05
Y95308105
WAVE LIFE SCIENCES LTD
$11M1.9M6.4%
06
G1110E107
BIOHAVEN LTD
$8M506K4.7%
07
CRBU
CARIBOU BIOSCIENCES INC
$8M4.7M4.6%
08
SPRO
SPERO THERAPEUTICS INC
$5M2.4M3.1%
09
ZNTL
ZENTALIS PHARMACEUTICALS INC
$4M954K2.3%
10
ORIC
ORIC PHARMACEUTICALS INC
$4M373K2.1%

Filing history

2026Q2Jun 30
$170M 28.7%
20 positionsView →
2026Q1Mar 31
$239M 1.0%
21 positionsView →
2025Q4Dec 31
$236M 37.9%
21 positionsView →
2025Q3Sep 30
$381M 33.9%
15 positionsView →
2025Q2Jun 30
$576M 15.0%
24 positionsLocked
2025Q1Mar 31
$501M 80.7%
24 positionsLocked
2024Q4Dec 31
$2.6B
26 positionsLocked